🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT03818412
Recruiting Not applicable

Circulating Tumor DNA in Soft Tissue Sarcoma

NCT03818412 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2019-01-17
Last updated
2026-06-23

Condition(s) studied

Soft Tissue Sarcoma

Investigational drug(s) / intervention(s)

Archival tumor tissue collection and blood draws

Archival tumor tissue collection and blood draws: Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.

Study summary

This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma. * Patients must have archival tissue from the diagnostic biopsy available. * Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist. * Age 18 years or older. * Eastern Cooperative Group (ECOG) performance status ≤ 2 * Ability to understand and willing to sign a written informed consent document and comply with study requirements. Exclusion Criteria: * Patients with benign histology * Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix. * Patients with planned neo-adjuvant chemotherapy. * Patients with regional nodal disease or unequivocal metastases * Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Princess Margaret Cancer Centre Toronto Ontario Recruiting

More University Health Network, Toronto trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03818412 on ClinicalTrials.gov ↗ ← All trials in Canada